Home / News

Pfizer Raises 2026 Outlook After Q3 Beat, Names Veteran Cecile Guegan CFO

• Pfizer reported Q3 adjusted EPS of 87 cents on revenue of $16.58 billion, beating LSEG estimates of 73 cents and $15.87 billion. • The company raised full-year revenue guidance to $62–$64 billion from $60.5–$62.5 billion and adjusted EPS to $2.95–$3.05. • Company veteran Cecile Guegan stepped in as chief financial officer this month. • Pfizer reaffirmed roughly $4 billion in Covid product sales for the year and targets about $9.7 billion in net savings through 2029.

Pfizer on Tuesday reported third-quarter results that topped Wall Street estimates and raised its full-year outlook, citing its "strong year-to-date performance," ongoing cost cuts and growing demand for newly launched and acquired products. Adjusted earnings came in at 87 cents per share against the 73 cents expected by analysts polled by LSEG, while revenue of $16.58 billion beat the $15.87 billion consensus. Revenue was relatively flat from a year earlier. Pfizer cited an operational decrease of $57 million, primarily due to lower Covid revenues, and a $15 million negative impact from foreign exchange, offset by strong sales of key products such as blood thinner Eliquis and cancer drug Padcev, both of which beat expectations. Net income was $3.24 billion, or 56 cents per share, compared with $3.54 billion, or 62 cents per share, a year earlier. The drugmaker now expects full-year revenue of $62 billion to $64 billion, up from a previous outlook of $60.5 billion to $62.5 billion; the low end would be roughly flat or slightly below 2025 revenue of $62.6 billion. Adjusted EPS guidance was raised to $2.95–$3.05 from $2.80–$3.00. Pfizer reaffirmed its Covid product outlook of roughly $4 billion for the year, with most Covid shot sales expected in the fourth quarter. Pfizer also announced that Cecile Guegan, who has held various finance leadership roles at the company over the past two decades, has stepped in as chief financial officer. The company is continuing its multiyear cost-cutting program, now targeting roughly $9.7 billion in net savings through 2029 to offset sharp declines in Covid product sales. Shares traded roughly flat in premarket trading after the report.